Finally, in our recent clinical study, treatment with ivacaftor resulted in significantly lower plasma HE4 concentrations in three independent cohorts of CF patients already at 1 month following initiation of therapy (Nagy et al., 2019). Here, WFDC2 is linked to cystic fibrosis.